Citadel Advisors
ABCL icon

Citadel Advisors’s AbCellera Biologics ABCL Stock Holding History

Citadel Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
429,500
+207,500
+93% +$747K ﹤0.01% 6708
2025
Q4 		$759K Sell
222,000
-15,300
-6% -$68.3K ﹤0.01% 8025
2025
Q3 		$1.19M Buy
237,300
+199,500
+528% +$879K ﹤0.01% 7155
2025
Q2 		$130K Buy
37,800
+14,300
+61% +$35.6K ﹤0.01% 11095
2025
Q1 		$52.4K Sell
23,500
-99,300
-81% -$285K ﹤0.01% 12269
2024
Q4 		$360K Buy
122,800
+54,000
+78% +$150K ﹤0.01% 9290
2024
Q3 		$179K Buy
68,800
+37,700
+121% +$104K ﹤0.01% 10313
2024
Q2 		$92.1K Sell
31,100
-1,400
-4% -$5.3K ﹤0.01% 11033
2024
Q1 		$147K Sell
32,500
-278,700
-90% -$1.42M ﹤0.01% 10794
2023
Q4 		$1.78M Sell
311,200
-38,700
-11% -$179K ﹤0.01% 5581
2023
Q3 		$1.61M Buy
349,900
+55,800
+19% +$339K ﹤0.01% 5615
2023
Q2 		$1.9M Sell
294,100
-16,700
-5% -$114K ﹤0.01% 5236
2023
Q1 		$2.34M Sell
310,800
-50,400
-14% -$458K ﹤0.01% 5059
2022
Q4 		$3.66M Sell
361,200
-38,900
-10% -$449K ﹤0.01% 4409
2022
Q3 		$3.96M Buy
400,100
+35,200
+10% +$386K ﹤0.01% 4270
2022
Q2 		$3.89M Buy
364,900
+169,100
+86% +$1.43M ﹤0.01% 4264
2022
Q1 		$1.91M Sell
195,800
-76,000
-28% -$720K ﹤0.01% 6189
2021
Q4 		$3.89M Buy
271,800
+29,600
+12% +$449K ﹤0.01% 4812
2021
Q3 		$4.85M Buy
242,200
+58,600
+32% +$1.04M ﹤0.01% 4356
2021
Q2 		$4.04M Buy
183,600
+136,200
+287% +$3.76M ﹤0.01% 4913
2021
Q1 		$1.61M Buy
+47,400
New +$1.89M ﹤0.01% 6929

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ABCL Position: Q1 2026 in Review

Citadel Advisors reduced its AbCellera Biologics (ABCL) stake by 26% in Q1 2026, selling an estimated $1.7M and leaving 1,361,105 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Citadel Advisors first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $17.4M in Q4 2020. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Citadel Advisors held 1,361,105 shares of AbCellera Biologics worth $4.75M as of Q1 2026.
  • Citadel Advisors sold 473,403 AbCellera Biologics shares in Q1 2026, an estimated $1.7M.
  • AbCellera Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4428 holding.
  • Citadel Advisors first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's AbCellera Biologics position peaked at $17.4M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.